Chemistry:Naminidil
From HandWiki
Naminidil (INN, USAN; developmental code name BMS-234303) is an ATP-sensitive potassium channel opener with vasodilator activity which was under development as a topical medication for the treatment of androgenic alopecia (pattern hair loss) but was never marketed.[1][2][3] The drug was under development by Bristol-Myers Squibb and reached phase 2 clinical trials by 2001.[1] One of the phase 2 trials compared naminidil, minoxidil, and placebo for alopecia.[3] However, no results of the study appear to have been made available.[3] Development of naminidil was discontinued by 2008.[1] In terms of chemical structure, naminidil is a guanidine derivative and is structurally distinct from minoxidil.[1][4]
See also
- List of investigational hair loss drugs
- ATP-sensitive potassium channel § Stimulation of hair growth
References
- ↑ 1.0 1.1 1.2 1.3 "Naminidil". 17 January 2008. https://adisinsight.springer.com/drugs/800016162.
- ↑ "Delving into the Latest Updates on Naminidil with Synapse". 20 July 2025. https://synapse.patsnap.com/drug/3183fb2090104188a9f3cb048311b553.
- ↑ 3.0 3.1 3.2 "Investigational medications in the treatment of alopecia". Expert Opinion on Investigational Drugs 14 (2): 177–184. February 2005. doi:10.1517/13543784.14.2.177. PMID 15757393.
- ↑ "Naminidil". PubChem. U.S. National Library of Medicine. https://pubchem.ncbi.nlm.nih.gov/compound/158438.
 |  |
